Chemed Corporation (CHE)
NYSE: CHE
· Real-Time Price · USD
450.76
-11.99 (-2.59%)
At close: Sep 10, 2025, 3:59 PM
406.00
-9.93%
After-hours: Sep 10, 2025, 05:56 PM EDT
Chemed Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Sep 30, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Segment Vitas Revenue | 420.45M | 415.57M | 230.68M | 224.84M | 225.43M | 216.82M | 204M | 196.07M | 177.34M | 547.13M | 195.36M | 478.51M | 485.95M | 469.95M | 12.22M |
| Segment Vitas Revenue Growth | +1.18% | +80.15% | +2.59% | -0.26% | +3.97% | +6.28% | +4.05% | +10.56% | -67.59% | +180.06% | -59.17% | -1.53% | +3.40% | +3746.07% | n/a |
| Segment Roto Rooter Revenue | 230.98M | 248.87M | n/a | 322.76M | 319.66M | 323.2M | n/a | 340.1M | 338.9M | 1.38B | n/a | 1.31B | 1.28B | 1.25B | n/a |
| Segment Roto Rooter Revenue Growth | -7.19% | n/a | n/a | +0.97% | -1.10% | n/a | n/a | +0.35% | -75.42% | n/a | n/a | +2.52% | +2.07% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 100.32M | 105.59M | 104.25M | 101.98M | 102.25M | 115.87M | 100.44M | 95.34M | 94.99M | 97.58M | 96.93M | 83.99M | 87.85M | 93.89M | 92.07M | 89.22M | 93.84M | 91.6M | 86.81M | 88.32M | 84.51M | 70.58M | 78.63M | 76.84M | 71.56M | 74.03M | 66.73M | 67.18M | 68.3M | 69M | 71.61M | 66.92M | 68.65M | 69.46M | 61.37M | 59.37M | 62.63M | 59.05M | 64.55M | 55.2M | 57.99M | 58.59M |
| Selling, General, and Administrative Revenue Growth | -4.99% | +1.28% | +2.23% | -0.27% | -11.75% | +15.37% | +5.34% | +0.38% | -2.66% | +0.67% | +15.40% | -4.39% | -6.43% | +1.97% | +3.20% | -4.92% | +2.44% | +5.52% | -1.71% | +4.50% | +19.74% | -10.23% | +2.33% | +7.38% | -3.34% | +10.93% | -0.66% | -1.64% | -1.02% | -3.64% | +7.00% | -2.53% | -1.16% | +13.18% | +3.37% | -5.20% | +6.07% | -8.53% | +16.95% | -4.82% | -1.01% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |